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Abstract
Although cross-sectional studies have shown a positive association between Se and cholesterol concentrations, a recent randomised
controlled trial in 501 elderly UK individuals of relatively low-Se status found that Se supplementation for 6 months lowered total plasma
cholesterol. The Danish PRECISE (PREvention of Cancer by Intervention with Selenium) pilot study (ClinicalTrials.gov ID: NCT01819649) was
a 5-year randomised, double-blinded, placebo-controlled trial with four groups (allocation ratio 1:1:1:1). Men and women aged 60–74 years
(n 491) were randomised to 100 (n 124), 200 (n 122) or 300 (n 119) μg Se-enriched yeast or matching placebo-yeast tablets (n 126) daily for
5 years. A total of 468 participants continued the study for 6 months and 361 participants, equally distributed across treatment groups,
continued for 5 years. Plasma samples were analysed for total and HDL-cholesterol and for total Se concentrations at baseline, 6 months and
5 years. The effect of different doses of Se supplementation on plasma lipid and Se concentrations was estimated by using linear mixed
models. Plasma Se concentration increased signiﬁcantly and dose-dependently in the intervention groups after 6 months and 5 years.
Total cholesterol decreased signiﬁcantly both in the intervention groups and in the placebo group after 6 months and 5 years, with small
and nonsigniﬁcant differences in changes in plasma concentration of total cholesterol, HDL-cholesterol, non-HDL-cholesterol and
total:HDL-cholesterol ratio between intervention and placebo groups. The effect of long-term supplementation with Se on plasma cholesterol
concentrations or its sub-fractions did not differ signiﬁcantly from placebo in this elderly population.
Key words: Selenium: Lipids: CVD: Cholesterol: Selenium supplementation: Randomised controlled trials
Se, an essential trace element, has a wide range of health effects
when incorporated as selenocysteine into selenoproteins(1,2).
Early studies in areas of low-Se status have implicated Se in
CVD risk(3,4). In Finland, increased cardiovascular morbidity
and mortality were observed in men with low serum Se(3),
whereas Se supplementation protected against cardiomyopathy
in the Keshan province of China(4). Cardiovascular beneﬁts of
Se could be mediated by the ability of selenoproteins, such as
glutathione peroxidase and selenoprotein S, to combat the
oxidative modiﬁcation of lipids, inhibit platelet aggregation and
reduce inﬂammation(5–11). However the evidence that Se status
affects CHD risk is equivocal(12–16), with a recent Cochrane
review ﬂagging major gaps in the available trial evidence,
especially with regard to long-term Se supplementation trials(16).
Cholesterol and its sub-fractions are recognised as important
cardiovascular risk factors(17,18). Several cross-sectional studies
have shown a positive association between higher Se status and
elevated concentrations of total and LDL-cholesterol(19–27).
However, higher Se status has also been linked to higher
circulating HDL-cholesterol(5,22–25), and results from prospective
studies have been inconsistent(28,29).
With the aim of showing the feasibility of conducting a large
randomised controlled trial of Se in cancer prevention in
European populations of relatively low-Se status, both UK and
* Corresponding author: Dr K. H. Winther, email kristian.winther@rsyd.dk
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Denmark set up the PREvention of Cancer by Intervention with
Selenium (PRECISE) pilot trials, recruiting elderly subjects from
1998 to 2001, using the same study protocol. Se-enriched yeast
was chosen as the intervention agent as it successfully reduced
cancer risk in the Nutritional Prevention of Cancer (NPC) trial(30)
and behaves similarly to wheat-Se in terms of absorption and
retention(31). In the UK PRECISE pilot trial (n 501), 6 months of
supplementation with 100, 200 or 300 μg/d Se-enriched yeast
had modest but statistically signiﬁcant beneﬁcial effects
on plasma lipids compared with placebo-yeast(32). Other
randomised controlled trials on the effect of Se supplementation
on circulating lipid concentrations mostly found no effect(33–39),
although several of the trials were small and short term.
On the basis of the results from the UK PRECISE trial, we
hypothesised that Se supplementation would have a beneﬁcial
effect on cholesterol concentrations in an elderly Danish
population with marginal Se deﬁciency. A considerable beneﬁt
over the UK study is that the Denmark PRECISE trial continued
for 5 years, enabling the effect of long-term supplementation to
be assessed for the ﬁrst time.
Methods
Study design
The Denmark PRECISE pilot study (ClinicalTrials.gov ID:
NCT01819649) was a single-centre, non-stratiﬁed, randomised,
double-blinded, placebo-controlled, multi-arm parallel clinical
trial with four groups (allocation ratio 1:1:1:1). The sample size
of this pilot study, before a proposed international trial of Se in
cancer prevention in the UK, Denmark and Sweden (PRECISE),
was set at 500 participants. This was considered sufﬁcient to
draw reasonable conclusions about recruitment, adherence and
loss to follow-up while keeping costs within reasonable
bounds. Because of these objectives, no formal power calcu-
lations were performed a priori. The funding necessary to
conduct the international PRECISE trial was not secured and
therefore it never took place.
Participants were men and women aged 60–74 years from the
County of Funen, Denmark. Invitation letters were sent out
based on a random sample from the Danish Civil Registration
System. From November 1998 to June 1999, we invited 2897
potential participants, of whom 630 accepted the invitation for a
visit to Odense University Hospital, where they were screened
for inclusion. Exclusion criteria were as follows: (i) a Southwest
Oncology Group performance status score >1, indicating
impairment in general well-being and activities of daily life;
(ii) active liver or kidney disease (alanine aminotransferase,
alkaline phosphatase, bilirubin or urea two standard deviations
above the normal reference range); (iii) previous diagnosis of
cancer (excluding non-melanoma skin cancer); (iv) diagnosed
HIV infection; (v) receiving immunosuppressive therapy;
(vi) unable to understand written and spoken information;
(vii) receiving ≥50 μg/d of Se supplements in the previous
6 months (by patient report).
Participants deemed suitable for inclusion provided blood
samples and were given yeast tablets for an open-label 4-week
placebo run-in phase. After this, potential participants returned
for a second visit for a ﬁnal evaluation of inclusion and exclusion
criteria and of participant adherence and satisfaction during the
run-in phase. Good adherence was deﬁned as taking >80 % of
the run-in phase tablets assessed by tablet count.
The 491 subjects who met the inclusion criteria, who dis-
played good adherence in the run-in phase and gave written
informed consent, were enroled and randomised to 0, 100, 200
or 300 μg of Se daily. The regional Data Protection Agency and
Scientiﬁc Ethical Committees of Vejle and Funen counties
approved the study (Journal number. 19980186).
Randomisation and interventions
Randomisation was computer-generated, blocked and non-
stratiﬁed and was performed at the Division of Epidemiology &
Biostatistics, University of Arizona, Arizona Cancer Center.
A badge number system secured blinding and correct dis-
tribution of Se doses. The responsibility of distributing tablets
was placed with pharmacists at Odense University Hospital.
Participating couples living at the same address were allocated
to the same intervention.
The intervention agent was the Se-enriched yeast Seleno-
Precise© and tablets were formulated and packaged by Pharma
Nord ApS. Analytical data (by inductively coupled-plasma
(ICP)-MS) for the three different strengths of SelenoPrecise©
are as follows: 100 µg tablets, 93–107 µg Se; 200 µg tablets,
186–214 µg Se; and 300 µg tablets, 279–321 µg Se. Speciation of
Se in SelenoPRECISE has been investigated previously, and the
selenised yeast, which was used as a source of Se, contained
selenomethionine at 54–60 % of the total Se, with unknown
seleno-compounds accounting for the remainder(40). The
placebo agent was an inactive spray-dried baker’s yeast,
comprising 250mg of yeast placebo, 80 mg of cellulose, 65 mg
of dicalcium phosphate and ≤5mg of other inactive ingredients,
identical in appearance to the Se tablets. Both intervention and
placebo tablets were coated with titanium oxide in order to
obtain identical smell and taste. Tablets were packaged in
blister packs of twenty-eight tablets, 7× 4. Participants, research
staff and investigators were blinded to treatment.
Sample and data collection and study outcomes
Participants were evaluated at Odense University Hospital at
baseline and at 6, 12, 18, 24, 36 and 60 months. Demographic
data and medical history including medication and supplement
use were collected at baseline. During each visit, medical status
was ascertained, side effects were registered and tablets were
counted. Adherence was deﬁned as in the run-in phase.
New tablets were handed out except at the 60-month visit.
Blood was drawn at 6, 12, 18, 24 and 60 months. Participants
were non-fasting. Heparinised plasma, serum, whole blood,
erythrocytes and buffy coat were prepared and stored at −80°C.
Reasons for participant withdrawal were recorded.
The pre-speciﬁed primary outcome of the pilot study was to
determine recruitment, adherence and drop-out rate of the
volunteers to ascertain the viability of conducting the main
PRECISE trial in Denmark. The pre-speciﬁed secondary outcomes
were as follows: (i) to determine the number of staff necessary to
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conduct the main PRECISE study; and (ii) to perfect questionnaires
and case report forms used at the participant trial visits.
Biochemical analyses
Total Se at baseline and at the 6-month and 5-year visits was
measured in lithium–heparin plasma at LGC Limited, by ICP-MS
with external calibration. The sample dilutions were introduced
into the plasma via a micro-ﬂow quartz concentric nebuliser,
operating in pumping mode at 0·1 rpm, and a Scott double-pass
spray chamber cooled to 2°C. The Se isotopes 77Se, 78Se and
82Se were measured in both H2-mode and He-mode using
collision cell ICP-MS (7700× ; Agilent Technologies) to reduce
the interferences on the Se isotopes. Each analysis comprised
three replicate measurements. Germanium was added online as
an internal standard to correct for any instrumental drift. In
addition, 2 % methanol was mixed online in order to compen-
sate for differences in carbon content between the samples and
standards that may cause variances in ionisation efﬁciency
leading to erroneous results. As the Se concentrations calculated
for all of the measured isotopes agreed well, only the data for
78Se in H2-mode were reported throughout. All reagents were of
the highest purity. Methanol (Optigrade; LGC) and nitric acid
(UltraPure; Romil) were used throughout. A stock solution
of 1000 mg/kg Se (Romil) was used to prepare the working
calibration standards (0–50 ng/g Se) freshly by gravimetric
dilution in 0·5 % (v/v) nitric acid. A matrix-certiﬁed reference
material, BCR-637 Human Serum, with a certiﬁed Se con-
centration of 81 (SD 7) µg/l Se (density corrected 79·1 ng/g), was
used for quality control of the total Se measurements. The Se
concentration found for BCR-637 was 78·3 (SD 2·7) µg/l Se
(sixteen independent replicates), indicating good accuracy of
the method. The intra-assay CV ranged from 0·5% for samples of
high-Se concentration to 3% for samples of low-Se concentration.
The interassay CV was 3·4%.
Total and HDL-cholesterol concentrations at baseline and at
the 6-month and 5-year visits were measured in lithium–heparin
plasma at the Department of Clinical Biochemistry, Odense
University Hospital, Denmark, using an Architect c16000
analyser (Abbott) with dedicated reagents. Measurements
were performed by means of enzymatic colorimetric analysis.
Traceability for total cholesterol and HDL-cholesterol was
ensured through participation in the National Reference System
for cholesterol (NRS/CHOL) established by the Clinical and
Laboratory Standards Institute with isotope dilution-MS as the
reference method and reference material from the National
Institute of Standard and Technology. Intra-assay/interassay
CV were 0·6/0·8 % for total cholesterol and 1·0/0·5 % for
HDL-cholesterol. As evidence of equivalence in the analytical
performance of the cholesterol-oxidase assays in the UK and
Denmark, a comparison of total cholesterol on forty-four serum
samples produced a limit of variation of 2 %.
Power calculations for intention-to-treat analysis
For the average sample size of 117 participants retained in each
treatment group after 6 months of follow-up and an uncorrected
two-sided signiﬁcance level of 0·05, the power to detect
underlying differences in 6-month changes of 0·20 mmol/l
(0·077 g/l) for total cholesterol, 0·05 mmol/l (0·019 g/l) for HDL-
cholesterol, 0·20mmol/l for non-HDL-cholesterol, and 0·15 for
total:HDL-cholesterol ratio, comparing any intervention group
with placebo, was 72·6, 64·3, 78·1 and 71·8 %, respectively.
Because of the smaller sample size of ninety participants
remaining in each group at the end of the 5-year follow-up
period and the lower correlation between lipid measurements
taken 5 years apart, the power to detect the same underlying
differences in lipid changes after 5 years was reduced to 37·8,
30·6, 39·8 and 30·6 %, respectively.
Statistical analysis
For the comparison of randomised groups, all trial participants
were assigned to their randomised treatment group, irrespective
of compliance (intention-to-treat analysis). The effect of differ-
ent doses of Se supplementation on changes in total cholesterol,
HDL-cholesterol, non-HDL-cholesterol and total:HDL-cholesterol
ratio after 6 months and 5 years was estimated by using linear
mixed models(32,41) with ﬁxed effects for treatment groups,
follow-up times and treatment-by-time interactions, and allow-
ing for random between-subject variations in both baseline lipid
levels (intercepts) and lipid changes over follow-up (time
slopes). These models provided the mean lipid changes from
baseline to 6 months and 5 years for each treatment group, as
well as the differences in mean lipid changes for the three active
treatment groups compared with placebo (treatment effects).
We evaluated treatment-effect modiﬁcations by sex, baseline
age group (< or ≥ 65 years), category of BMI (< or ≥25 kg/m2),
baseline plasma Se concentration (< or ≥90 ng/g) and baseline
lipid concentrations (< or ≥6 mmol/l for total cholesterol,
1·5mmol/l for HDL-cholesterol, 4·5mmol/l for non-HDL-
cholesterol and 4 for total:HDL-cholesterol ratio) by including
all main terms and interactions between treatment group, time
and the corresponding covariate as ﬁxed effects in the above
mixed models. In sensitivity analyses, we excluded visits after
participants received lipid-lowering medications at baseline or
during the intervention period.
In addition to the intention-to-treat analysis, we evaluated the
cross-sectional association between plasma Se and lipid con-
centrations at baseline and the longitudinal associations
between changes in plasma Se and lipid concentrations after
6 months and 5 years. We used linear mixed models with
random intercepts, random time slopes and ﬁxed slopes for
baseline Se levels and Se changes at 6 months and 5 years(32,42)
to estimate the mean difference in baseline lipid levels per
50 ng/g increase in baseline Se concentrations (cross-sectional
association), as well as the mean lipid changes from baseline
to 6 months and 5 years for each 50 ng/g change in the
corresponding Se concentration (longitudinal associations). We
also categorised baseline Se concentrations and Se changes into
quartiles in the above mixed model and compared mean
baseline lipid concentrations across quartiles of baseline Se
and mean lipid changes after 6 months and 5 years across
quartiles of Se change. Cross-sectional and longitudinal
associations were adjusted for baseline age (continuous), sex,
smoking status (never, former, or current), alcohol drinking
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(≤2, 3–10, or >10 drinks/week), BMI (continuous) and changes
in lipid-lowering medications over time. All reported P values
were two-sided and not adjusted for multiple testing. Statistical
analyses were performed with Stata, version 13 (StataCorp).
Results
Participants
Of the 491 randomised participants, twenty-three dropped out of
treatment before 6 months of follow-up, 107 participants
dropped out between 6 months and 5 years, and the remaining
361 participants completed the 5-year follow-up period (Fig. 1).
The 130 participants who withdrew before the end of the study
period were equally distributed across treatment groups
(P= 0·91). Lipid measurements were available for 490 partici-
pants at baseline, for 435 at 6 months and for 358 at 5 years
(Fig. 1). Participants with and without available lipid measure-
ments at 6 months and 5 years did not differ in their baseline
characteristics (data not shown). Three of the ninety participants
allocated to placebo (3·3 %) had plasma Se concentrations more
than two interquartile ranges above the median at 5 years, and
Randomized (n 491)
Drop-outs before 6 months
(n 6)
Adverse events: 2
Adverse reactions: 2
Noncompliance: 1
Withdrew consent: 1
6-month lipid measurements 
available (n 113)
Missing blood sample: 9
6-month lipid measurements
available (n 110)
Missing blood sample: 7
6-month lipid measurements
available (n 104)
Missing blood sample: 9
Drop-outs between 6 months
and 5 years (n 26)
Adverse events: 2
Adverse reactions: 3
Deaths: 5
Withdrew consent: 10
Unknown/personal
reasons: 6
Drop-outs between 6 months
and 5 years (n 31)
Adverse events: 11
Adverse reactions: 5
Deaths: 6
Withdrew consent: 5
Unknown/personal
reasons: 4
Drop-outs between 6 months
and 5 years (n 27)
Adverse events: 10
Adverse reactions: 6
Deaths: 2
Withdrew consent: 3
Unknown/personal
reasons: 6
Drop-outs between 6 months
and 5 years (n 23)
Adverse events: 4
Adverse reactions: 4
Deaths: 8
Withdrew consent: 2
Unknown/personal
reasons: 5
5-year lipid measurements
available (n 90)
5-year lipid measurements
available (n 89)
Missing blood sample: 1
Plasma aliquots exhausted: 1
5-year lipid measurements
available (n 89)
Missing blood sample: 1
Analyzed: lipid measures
available at baseline, 6 months,
or 5 years (n 126)
Analyzed: lipid measures
available at baseline, 6 months,
or 5 years (n 124)
Analyzed: lipid measures
available at baseline, 6 months,
or 5 years (n 119)
Assessed for eligibility (n 2897)
Declined to participate: 2267
Did not meet inclusion criteria: 63
Did not complete placebo run-in: 5
Withdrew consent: 38
Unknown/personal reasons: 33
Excluded (n 2406)
Allocated to placebo (n 126)
Received allocation: 126
Allocated to 300 µg/d (n 119)
Received allocation: 119
Allocated to 200 µg/d (n 122)
Received allocation: 122
Allocated to 100 µg/d (n 124)
Received allocation: 124
Baseline lipid measurements
available (n 123)
Plasma aliquots exhausted: 1
Baseline lipid measurements
available (n 126)
Baseline lipid measurements
available (n 122)
Baseline lipid measurements
available (n 119) 
Drop-outs before 6 months
(n 2)
Adverse events: 2
Drop-outs before 6 months
(n 10)
Adverse events: 3
Adverse reactions: 3
Deaths: 1
Unknown/personal
reasons: 3
Drop-outs before 6 months
(n 5)
Adverse events: 1
Adverse reactions: 2
Withdrew consent: 1
Unknown/personal
reasons: 1
Missing blood sample: 8
6-month lipid measurements
available (n 108)
5-year lipid measurements
available (n 90)
Analyzed: lipid measures 
available at baseline, 6 months,
or 5 years (n 122)
Fig. 1. Study flow diagram.
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hence non-protocol use of over-the-counter Se was deemed to
be rare. Thirty participants were receiving lipid-lowering medi-
cations at baseline and forty-eight at 5 years, with no signiﬁcant
differences between treatment groups at any time (P= 0·20 and
0·40, respectively).
Intention-to-treat analysis
The mean of age and plasma Se concentration at baseline were
66·1 (SD 4·1) years and 86·5 (SD 16·3) ng/g (88·6 (SD 16·7) μg/l),
respectively. Mean baseline levels of total cholesterol, HDL-
cholesterol, non-HDL-cholesterol and total:HDL-cholesterol
ratio were 6·01 (SD 0·94) mmol/l (2·324 (SD 0·362) g/l), 1·59 (SD
0·38) mmol/l (0·616 (SD 0·147) g/l), 4·42 (SD 0·94) mmol/l (1·708
(SD 0·365) g/l) and 3·95 (SD 1·01), respectively. There were no
signiﬁcant differences between treatment groups at baseline in
terms of plasma Se concentrations, lipid concentrations or other
participant characteristics (Table 1).
After 6 months of supplementation, plasma Se increased
signiﬁcantly and proportionally to the assigned dose in the
three active treatment groups, but remained unchanged in the
placebo group (Table 2). Compared with placebo, the mean
changes in plasma Se concentrations were 65·7 ng/g (95 % CI
55·7, 75·6 ng/g) after 6 months of Se supplementation at
100 µg/d, 121·7 ng/g (95% CI 111·7, 131·7 ng/g) at 200 µg/d and
170·7 ng/g (95% CI 160·5, 180·8 ng/g) at 300 µg/d (P for homo-
geneity of changes across the four treatment groups <0·01). Lipid
concentrations, however, evolved similarly, with no signiﬁcant
differences across the four treatment groups. Compared with
placebo, the mean changes in total cholesterol concentrations
were -0·07mmol/l (95 % CI −0·23, 0·09mmol/l) after 6 months of
Se supplementation at 100 µg/d, 0·06mmol/l (95 % CI −0·10,
0·21mmol/l) at 200 µg/d and 0·02mmol/l (95 % CI −0·14, 0·18
mmol/l) at 300 µg/d (P for homogeneity of changes across the
four treatment groups= 0·45). The mean changes at 6 months in
HDL-cholesterol, non-HDL-cholesterol and total:HDL-cholesterol
ratio were also small and not statistically signiﬁcant (Table 2).
After 5 years of Se supplementation, there were still no
signiﬁcant differences in lipid changes between the three active
treatment groups and the placebo group (Table 2). Although
results were similar after excluding participants who received lipid-
lowering medication during the intervention period, small but
Table 1. Baseline characteristics of trial participants overall and by treatment group
(Numbers and percentages; mean values and standard deviations)
Se dose (µg/d)
Overall Placebo 100 200 300
Characteristic n % n % n % n % n % P*
Participants 491 126 124 122 119
Age (years) 0·13
Mean 66·1 65·4 66·4 66·3 66·5
SD 4·1 3·8 4·2 4·4 4·1
Sex 0·49
Men 255 51·9 60 47·6 70 56·5 66 54·1 59 49·6
Women 236 48·1 66 52·4 54 43·5 56 45·9 60 50·4
Smoking status 0·49
Never 160 32·6 35 27·8 42 33·9 40 32·8 43 36·2
Former 185 37·7 48 38·1 47 37·9 52 42·6 38 31·9
Current 146 29·7 43 34·1 35 28·2 30 24·6 38 31·9
Alcohol drinking (drinks/week) 0·76
≤ 2 170 34·6 47 37·3 41 33·1 40 32·8 42 35·3
3–10 209 42·6 48 38·1 51 41·1 55 45·1 55 46·2
> 10 112 22·8 31 24·6 32 25·8 27 22·1 22 18·5
BMI (kg/m2) 0·40
Mean 26·8 26·5 27·1 27·2 26·5
SD 4·1 4·0 4·0 4·3 4·0
Use of lipid-lowering medication 30 6·1 8 6·3 12 9·7 6 4·9 4 3·4 0·20
Total cholesterol (mmol/l) 0·24
Mean 6·01 5·91 6·02 5·98 6·15
SD 0·94 0·86 0·99 0·93 0·95
HDL-cholesterol (mmol/l) 0·35
Mean 1·59 1·63 1·58 1·55 1·61
SD 0·38 0·42 0·34 0·37 0·39
Non-HDL-cholesterol (mmol/l) 0·18
Mean 4·42 4·28 4·44 4·43 4·54
SD 0·94 0·90 0·98 0·94 0·94
Total:HDL-cholesterol ratio 0·37
Mean 3·95 3·83 3·95 4·04 4·01
SD 1·01 1·03 0·96 1·02 1·04
Plasma Se (ng/g) 0·17
Mean 86·5 86·0 87·5 88·3 83·9
SD 16·3 15·2 16·4 16·2 17·1
* P value for homogeneity of means or proportions across the four treatment groups.
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Table 2. Effect of selenium supplementation on changes in plasma lipid and selenium concentrations after 6 months and 5 years*
(Mean values and standard deviations; 95% confidence intervals)
Se dose (µg/d)
Placebo 100 200 300
Variable Mean SD Mean SD Mean SD Mean SD P†
Total cholesterol (mmol/l)
At baseline 5·91 0·86 6·02 0·99 5·98 0·93 6·15 0·95
At 6 months 5·71 0·78 5·75 0·93 5·84 0·95 5·97 0·91
Change from baseline to 6 months
Mean −0·19 −0·26 −0·13 −0·17
95% CI −0·30, −0·08 −0·37, −0·15 −0·25, −0·02 −0·28, −0·05
Difference in change 0·45
Mean 0 −0·07 0·06 0·02
95% CI Ref. −0·23, 0·09 −0·10, 0·21 −0·14, 0·18
P 0·38 0·49 0·80
At 5 years 5·72 0·84 5·76 1·08 5·64 0·96 5·95 1·19
Change from baseline to 5 years
Mean −0·20 −0·30 −0·40 −0·16
95% CI −0·37, −0·04 −0·46, −0·13 −0·56, −0·23 −0·32, 0·01
Difference in change 0·19
Mean 0 −0·09 −0·19 0·05
95% CI Ref. −0·33, 0·14 −0·42, 0·04 −0·18, 0·28
P 0·43 0·11 0·69
HDL-cholesterol (mmol/l)
At baseline 1·63 0·42 1·58 0·34 1·55 0·37 1·61 0·39
At 6 months 1·62 0·40 1·55 0·31 1·52 0·35 1·56 0·38
Change from baseline to 6 months
Mean −0·02 −0·02 −0·02 −0·05
95% CI −0·05, 0·01 −0·05, 0·01 −0·05, 0·01 −0·08, −0·02
Difference in change 0·49
Mean 0 −0·01 0·00 −0·03
95% CI Ref. −0·05, 0·03 −0·05, 0·04 −0·08, 0·01
P 0·70 0·92 0·16
At 5 years 1·69 0·45 1·68 0·38 1·56 0·39 1·65 0·42
Change from baseline to 5 years
Mean 0·03 0·07 0·00 0·01
95% CI −0·01, 0·08 0·03, 0·12 −0·04, 0·05 −0·04, 0·05
Difference in change 0·13
Mean 0 0·04 −0·03 −0·03
95% CI Ref. −0·03, 0·10 −0·09, 0·03 −0·09, 0·04
P 0·25 0·33 0·41
Non-HDL-cholesterol (mmol/l)
At baseline 4·28 0·90 4·44 0·98 4·43 0·94 4·54 0·94
At 6 months 4·08 0·80 4·20 0·93 4·33 0·94 4·41 0·87
Change from baseline to 6 months
Mean −0·17 −0·23 −0·11 −0·12
95% CI −0·28, −0·07 −0·34, −0·13 −0·22, −0·01 −0·23, −0·01
Difference in change 0·35
Mean 0 −0·06 0·06 0·05
95% CI Ref. −0·21, 0·09 −0·09, 0·21 −0·10, 0·20
P 0·43 0·43 0·49
At 5 years 4·03 0·84 4·09 0·99 4·08 0·91 4·30 1·11
Change from baseline to 5 years
Mean −0·24 −0·37 −0·40 −0·16
95% CI −0·40, −0·08 −0·53, −0·21 −0·56, −0·24 −0·32, −0·01
Difference in change 0·13
Mean 0 −0·13 −0·16 0·08
95% CI Ref. −0·36, 0·09 −0·38, 0·06 −0·15, 0·30
P 0·25 0·16 0·51
Total:HDL-cholesterol ratio
At baseline 3·83 1·03 3·95 0·96 4·04 1·02 4·01 1·04
At 6 months 3·70 0·94 3·83 0·91 4·01 0·97 4·01 1·00
Change from baseline to 6 months
Mean −0·10 −0·12 −0·06 0·00
95% CI −0·19, −0·01 −0·20, −0·03 −0·15, 0·02 −0·09, 0·09
Difference in change 0·26
Mean 0 −0·02 0·04 0·10
95% CI Ref. −0·14, 0·10 −0·08, 0·16 −0·03, 0·22
P 0·76 0·54 0·12
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statistically signiﬁcant decreases (P=0·04) in non-HDL-cholesterol
and 0·20 (P=0·02) in total:HDL-cholesterol ratio were seen at Se
supplementation of 100 µg/d (Table 3). There were no signiﬁcant
differences in treatment effects across baseline age groups, sex,
category of BMI, or baseline plasma Se concentration or baseline
lipid concentrations, after excluding men and women receiving
lipid-lowering medications (data not shown).
Association between plasma Se and lipid concentrations
In cross-sectional analyses at baseline, a 50 ng/g increase in plasma
Se was signiﬁcantly associated with mean increases of 0·47mmol/l
(95% CI 0·24, 0·70mmol/l; Ptrend<0·001) in total cholesterol levels
and 0·41mmol/l (95% CI 0·17, 0·64mmol/l; Ptrend=0·001) in non-
HDL-cholesterol levels. HDL-cholesterol and total:HDL-cholesterol
ratio were not signiﬁcantly associated with plasma Se at baseline
(Table 4). In longitudinal analyses, a 50 ng/g increase in plasma Se
over time was not related to signiﬁcant changes in total HDL-
cholesterol, non-HDL-cholesterol and total:HDL-cholesterol ratio
after 6 months or 5 years (Table 5).
Adverse events
Twenty-two participants died during the 5-year follow-up period
and thirty-ﬁve participants discontinued the study because of
non-fatal adverse events (Fig. 1), with no signiﬁcant differences
across treatment groups (P = 0·29 and 0·14, respectively).
Twenty-ﬁve participants withdrew because of adverse reactions
to treatment (Fig. 1), which were mainly hair loss, skin reactions
and grooved nails. These reactions were equally associated with
Se or placebo and were independent of Se dose (P= 0·84).
Discussion
Contrary to our working hypothesis, Se supplementation showed
no beneﬁt over placebo on cholesterol concentrations after
6 months or 5 years in this elderly Danish population. Our ﬁndings
were different from those of the UK PRECISE pilot trial, despite
both study populations having similar mean baseline plasma Se
concentrations (88·8 ng/g (91·2 μg/l) in UK PRECISE and 86·5 ng/g
(88·6 μg/l) in Denmark PRECISE). In the UK study, compared with
placebo, total plasma cholesterol and non-HDL-cholesterol
concentrations decreased signiﬁcantly in the 100 and 200 μg/d
Se supplementation groups, whereas HDL-cholesterol concentra-
tions increased signiﬁcantly in the 300 μg/d group. In addition, the
total:HDL-cholesterol ratio decreased progressively with increasing
Se dose(32). We could not reproduce the UK PRECISE ﬁndings of
beneﬁcial effects of Se supplementation on total cholesterol or on
the total:HDL-cholesterol ratio at 6 months, as beneﬁcial changes
in the intervention groups were matched by similar changes in the
placebo group. This was also the case at 5 years, highlighting the
internal consistency of the Danish results after both short-term and
long-term intervention.
Table 2 Continued
Se dose (µg/d)
Placebo 100 200 300
Variable Mean SD Mean SD Mean SD Mean SD P†
At 5 years 3·59 1·00 3·55 0·81 3·78 0·96 3·77 0·99
Change from baseline to 5 years
Mean −0·20 −0·37 −0·29 −0·12
95% CI −0·34, −0·06 −0·51, −0·23 −0·43, −0·15 −0·26, 0·02
Difference in change 0·06
Mean 0 −0·17 −0·09 0·08
95% CI Ref. −0·37, 0·02 −0·29, 0·10 −0·12, 0·27
P 0·08 0·35 0·43
Plasma Se (ng/g)
At baseline 86·0 15·2 87·5 16·4 88·3 16·2 83·9 17·1
At 6 months 85·3 14·2 152·4 23·7 209·1 41·5 253·7 54·1
Change from baseline to 6 months
Mean −0·9 64·8 120·9 169·8
95% CI − 8·0, 6·2 57·8, 71·8 113·8, 127·9 162·5, 177·0
Difference in change <0·001
Mean 0 65·7 121·7 170·7
95% CI Ref. 55·7, 75·6 111·7, 131·7 160·5, 180·8
P <0·001 <0·001 <0·001
At 5 years 87·7 24·2 158·3 28·3 222·2 40·6 276·5 78·7
Change from baseline to 5 years
Mean 1·3 70·8 133·7 192·3
95% CI −8·6, 11·3 60·7, 80·8 123·7, 143·8 182·2, 202·4
Difference in change <0·001
Mean 0 69·4 132·4 190·9
95% CI Ref. 55·3, 83·6 118·2, 146·5 176·7, 205·1
P <0·001 <0·001 <0·001
Ref., referent values.
* Results were obtained from linear mixed models with fixed treatment-by-time interactions and random between-subject variations in both baseline lipid levels and lipid changes
over time.
† Overall P value comparing the three active treatment groups with placebo.
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Table 4. Cross-sectional association between plasma selenium and lipid levels at baseline*
(Mean values and standard deviations; 95% confidence intervals)
Quartile of baseline Se (ng/g)
50 ng/g increase in
baseline Se First (43–76) Second (77–85) Third (86–95) Fourth (96–159)
Variable Mean SD Mean SD Mean SD Mean SD Mean SD Ptrend†
Median baseline Se (ng/g) 85 70 80 89 104
Participants (n) 488 126 129 114 119
Total cholesterol (mmol/l)
At baseline 6·01 0·93 5·70 0·94 6·06 0·88 6·11 0·90 6·19 0·94
Adjusted mean difference <0·001
Mean 0·47 0 0·33 0·43 0·45
95% CI 0·24, 0·70 Ref. 0·13, 0·54 0·23, 0·64 0·24, 0·66
HDL-cholesterol (mmol/l)
At baseline 1·59 0·38 1·52 0·37 1·58 0·36 1·64 0·36 1·64 0·41
Adjusted mean difference 0·16
Mean 0·06 0 0·03 0·09 0·05
95% CI −0·03, 0·15 Ref. −0·05, 0·11 0·01, 0·17 −0·03, 0·13
Non-HDL-cholesterol (mmol/l)
At baseline 4·42 0·94 4·18 0·97 4·48 0·89 4·47 0·92 4·55 0·96
Adjusted mean difference 0·001
Mean 0·41 0 0·31 0·35 0·40
95% CI 0·17, 0·64 Ref. 0·10, 0·51 0·13, 0·56 0·18, 0·61
Total:HDL-cholesterol ratio
At baseline 3·95 1·01 3·95 1·10 3·99 0·94 3·87 0·93 3·98 1·06
Adjusted mean difference 0·17
Mean 0·15 0 0·12 0·03 0·18
95% CI −0·10, 0·39 Ref. −0·10, 0·33 −0·19, 0·25 −0·04, 0·41
Ref., referent values.
* Results were obtained from linear mixed models with random between-subject variations in baseline lipid levels and adjusted for baseline age (continuous), sex, smoking status
(never, former, or current), alcohol drinking (≤2, 3–10, or >10 drinks/week), BMI (continuous) and use of lipid-lowering medications.
† P value for linear trend using an ordinal variable with the median baseline Se level in each quartile.
Table 3. Effect of selenium supplementation on changes in plasma lipid concentrations after 6 months and 5 years in participants not receiving lipid-lowering
medications* (Mean values and 95% confidence intervals)
Difference in change from baseline
Placebo Se 100 µg/d Se 200 µg/d Se 300 µg/d
Variable Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI P†
Total cholesterol (mmol/l)
6 months 0 Ref. −0·13 −0·28, 0·03 0·00 −0·15, 0·16 −0·02 −0·17, 0·14 0·30
P 0·11 0·97 0·82
5 years 0 Ref. −0·15 −0·34, 0·04 −0·16 −0·35, 0·03 0·03 −0·16, 0·21 0·10
P 0·11 0·11 0·77
HDL-cholesterol (mmol/l)
6 months 0 Ref. −0·03 −0·07, 0·02 0·00 −0·05, 0·04 −0·03 −0·08, 0·01 0·38
P 0·27 0·91 0·15
5 years 0 Ref. 0·03 −0·03, 0·10 −0·02 −0·09, 0·04 −0·02 −0·08, 0·04 0·32
P 0·31 0·52 0·53
Non-HDL-cholesterol (mmol/l)
6 months 0 Ref. −0·10 −0·24, 0·04 0·01 −0·14, 0·15 0·02 −0·13, 0·16 0·35
P 0·18 0·93 0·81
5 years 0 Ref. −0·19 −0·37, −0·01 −0·13 −0·31, 0·04 0·05 −0·13, 0·22 0·03
P 0·04 0·14 0·58
Total:HDL-cholesterol ratio
6 months 0 Ref. −0·03 −0·15, 0·09 0·00 −0·12, 0·11 0·07 −0·05, 0·19 0·43
P 0·63 0·94 0·28
5 years 0 Ref. −0·20 −0·36, −0·03 −0·07 −0·24, 0·10 0·04 −0·12, 0·20 0·03
P 0·02 0·42 0·65
Ref., referent values.
* Results were obtained from linear mixed models with fixed treatment-by-time interactions and random between-subject variations in both baseline lipid levels and lipid changes
over time, excluding visits after participants received lipid-lowering medications.
† Overall P value comparing the three active treatment groups with placebo.
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The different ﬁndings in the UK and Danish PRECISE trials
cannot be easily explained, as the two populations were of the
same age, had similar blood-lipid levels and Se status, and
received identical interventions. We could not explore the
possibility that the different results might relate to genetic
differences, but it seems unlikely, as both populations were
almost exclusively Caucasian. Alternatively, there may have
been differences in the intake of dietary macro- and micro-
nutrients between UK and Danish populations that could have
modiﬁed the effects of additional Se on blood lipids. For
instance, at the time of this intervention there was national
concern in Denmark about the potentially adverse effect of high
levels of trans-fatty acids (TFA) on cholesterol levels. This
concern culminated in the introduction of legislation in 2004 to
limit the content of industrially produced TFA in foods to <2 %
energy(43) Although recruitment to this study took place before
this legislation (December 1998 to July 1999), there is evidence
from the TRANSFAIR study to suggest that a lower intake of TFA
in Denmark over that period might have affected lipid
concentrations in Denmark(44). Indeed, in the Copenhagen City
Heart Study(45), total cholesterol concentrations in participants
aged 60–74 years decreased between 1991–1994 and 2001–2003
from 6·1 to 5·5mmol/l in men and from 6·8 to 5·9mmol/l in
women (A Langsted, JJ Freiberg, A Tybjaerg-Hansen, et al.,
unpublished results). However, secular declining trends in cho-
lesterol levels were also reported in the UK in the period leading
up to the PRECISE trial, with population total cholesterol falling
4·2 % from 1981 to 2000(46).
Table 5. Longitudinal association between changes in plasma selenium and lipid levels after 6 months and 5 years*
(Mean values and standard deviations; 95% confidence intervals)
Quartile of Se change (ng/g)
50 ng/g increase in
Se over time First (−48 to 22) Second (23 to 87) Third (88 to 146) Fourth (147 to 468)
Variable Mean SD Mean SD Mean SD Mean SD Mean SD P†
Median Se change (ng/g) 87 − 2 60 112 180
Participants (n)
6 months 432 108 121 106 97
5 years 356 89 78 92 97
Total cholesterol (mmol/l)
At 6 months −0·18 0·59 −0·20 0·64 −0·24 0·55 −0·09 0·56 −0·20 0·61
Adjusted difference in change 0·11
Mean 0·02 0 −0·04 0·12 −0·01
95% CI −0·02, 0·05 Ref. −0·18, 0·10 −0·02, 0·26 −0·16, 0·14
At 5 years −0·27 0·82 −0·25 0·81 −0·32 0·78 −0·29 0·89 −0·24 0·80
Adjusted difference in change 0·65
Mean 0·01 0 −0·10 −0·07 0·00
95% CI −0·03, 0·04 Ref. −0·29, 0·09 −0·26, 0·11 −0·19, 0·18
HDL-cholesterol (mmol/l)
At 6 months −0·03 0·16 −0·02 0·19 −0·02 0·16 −0·02 0·16 −0·04 0·15
Adjusted difference in change 0·77
Mean 0·00 0 0·00 −0·01 −0·02
95% CI −0·01, 0·01 Ref. −0·04, 0·04 −0·05, 0·04 −0·06, 0·02
At 5 years 0·03 0·23 0·03 0·22 0·03 0·21 0·07 0·25 0·00 0·24
Adjusted difference in change 0·39
Mean 0·00 0 0·00 0·01 −0·04
95% CI −0·01, 0·01 Ref. −0·06, 0·06 −0·05, 0·07 −0·10, 0·02
Non-HDL-cholesterol (mmol/l)
At 6 months −0·16 0·55 −0·18 0·58 −0·22 0·53 −0·07 0·54 −0·16 0·57
Adjusted difference in change 0·08
Mean 0·02 0 −0·04 0·12 0·01
95% CI −0·01, 0·05 Ref. −0·17, 0·09 −0·01, 0·26 −0·13, 0·15
At 5 years −0·31 0·79 −0·28 0·76 −0·36 0·76 −0·35 0·84 −0·24 0·81
Adjusted difference in change 0·39
Mean 0·00 0 −0·10 −0·08 0·03
95% CI −0·03, 0·04 Ref. −0·29, 0·08 −0·26, 0·10 −0·14, 0·21
Total:HDL-cholesterol ratio
At 6 months −0·07 0·45 −0·10 0·47 −0·11 0·43 −0·01 0·50 −0·06 0·42
Adjusted difference in change 0·22
Mean 0·02 0 −0·02 0·09 0·03
95% CI −0·01, 0·04 Ref. −0·13, 0·09 −0·03, 0·20 −0·09, 0·14
At 5 years −0·26 0·70 −0·19 0·61 −0·33 0·69 −0·36 0·77 −0·16 0·70
Adjusted difference in change 0·10
Mean 0·00 0 −0·13 −0·12 0·04
95% CI −0·04, 0·03 Ref. −0·30, 0·03 −0·28, 0·05 −0·12, 0·20
Ref., referent values.
* Results were obtained from linear mixed models with random between-subject variations in both baseline lipid levels and lipid changes over time and adjusted for baseline Se
levels (continuous), age (continuous), sex, smoking status (never, former, or current), alcohol drinking (≤ 2, 3–10, or >10 drinks/week), BMI (continuous) and changes in
lipid-lowering medications over time.
† Overall P value comparing the three highest quartiles of Se change with the lowest quartile.
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A difference between the Danish and UK populations over this
period was that Denmark introduced I fortiﬁcation in 1998
because of low I intake (47). In the county of Funen, from where
participants were recruited, the average 24 h I excretion in
1988 was reported to be 85 μg, indicative of moderate I
deﬁciency(47,48). Chronic I deﬁciency increases thyroid stimulating
hormone (TSH) concentration and produces a thyroid hormone
pattern consistent with subclinical hypothyroidism, characterised
by raised plasma total and LDL-cholesterol concentrations(49,50).
Hence, it is possible that beneﬁts to serum lipids from I
fortiﬁcation over the period of the trial may have camouﬂaged
any beneﬁcial effect of Se supplementation in the Danish
cohort(51). The effect of Se supplementation on thyroid function
has been investigated in our study population and minute and
dose-dependent decreases in serum TSH and FT4 concentrations
were found(52). This could hypothetically improve the lipid
proﬁle(53), but our results suggest that the observed effects on
thyroid function were too small to affect lipid metabolism.
In cross-sectional analyses we observed signiﬁcant positive
associations between plasma Se concentrations and total and
non-HDL-cholesterol concentrations (Table 4), as found in
previous cross-sectional studies(19–27). Although such observa-
tions have previously raised concern that Se intake might have
adverse effects on blood cholesterol, our data indicate that
these cross-sectional associations are unlikely to be the result of
a causal effect of Se intake on lipid concentrations.
This study has several limitations. Participants were invited
via a random sample from the Danish Civil Registration System.
About 20 % accepted the invitation and this constitutes a
potential selection bias. The narrow age range of participants
(60–74 years) limits the applicability of our ﬁndings to a general
population, and the relatively low baseline Se status makes it
difﬁcult to extend our ﬁnding to populations with higher
baseline Se status – for example, the USA. As blood samples
were collected in a non-fasting state with no information
available on time since last meal, we were unable to assess the
concentration of plasma TAG, another CVD risk factor(54). The
lack of comparable dietary data in the Danish and UK PRECISE
populations limits the validity of comparisons between the two
studies – for example, differences in alcohol intake, which
inﬂuences lipid metabolism(55,56), were not extracted in the UK
PRECISE study. Furthermore, these ﬁndings come from post hoc
analyses of a trial that was not speciﬁcally designed and
powered to address our study questions, and hence they need
to be interpreted with caution. Post hoc power calculations,
with set absolute differences of 0·20mmol/l for total and non-
HDL-cholesterol, 0·05mmol/l for HDL-cholesterol and 0·15 for
total:HDL-cholesterol ratio, corresponding approximately to the
effects detected in the UK PRECISE study, showed that our
study was underpowered to ﬁnd the same differences after
6 months. In addition to the power calculations, 95 % CI are
given in the results section, to express the amount of uncer-
tainty about the effect estimates(57). Meanwhile, the lack of
observed effects are not likely because of low bioavailablity of
the formulation used, as the Se concentration in whole blood
from our trial participants was higher (P<0·001) than that
obtained with synthetic L-selenomethionine in a comparable
group of Danes, both groups having been treated with 300 μg
Se/d(40). Despite the limitations mentioned, this is the only
randomised, placebo-controlled trial that has examined the
effect of long-term Se supplementation on plasma cholesterol
and its sub-fractions.
In summary, we conclude that long-term Se supplementation
did not alter cholesterol concentrations in this Danish elderly
population. Any beneﬁcial effects were matched in the placebo
group, and the ﬁndings from the UK PRECISE pilot trial could
therefore not be reproduced. However, our ﬁndings show that
long-term supplementation with up to 300 μg/d Se (as Se yeast)
had no detectable adverse effects in an elderly population of
relatively low-Se status. In view of the potential beneﬁt of
raising Se status on some health conditions (e.g. mild Graves’
orbitopathy), these ﬁndings are reassuring(2,58).
Acknowledgements
The authors acknowledge Professor Kim Overvad for his
intellectual input in the planning of the DK PRECISE pilot trial,
Ann Knoop for her intellectual input in the early phases of this
study and Peter Schnohr for his help with obtaining data from
the Copenhagen City Heart Study.
This study was supported by the Danish Cancer Society; the
Research Foundation of the County of Funen; Cypress Systems
Inc.; the Danish Veterinary and Food Administration; the
Council of Consultant Physicians, Odense University Hospital;
the Clinical Experimental Research Foundation at Department
of Oncology, Odense University Hospital; K.A Rohde’s
Foundation; Dagmar Marshall’s Foundation. Pharma Nord ApS,
Vejle, Denmark provided the selenium and placebo tablets.
No funders had any role in the design, analysis or writing
of this article.
M. P. R. and S. C. designed research; F. C., K. H. W. and S. C.
conducted research; R. P.-B., E. G., M. N., B. A. G. and S. S.
analysed data; R. P.-B. performed statistical analysis; F. C. and
K. H. W. wrote the manuscript; F. C. had primary responsibility
for ﬁnal content; R. P.-B., M. P. R., E. G., M. N., B. A. G., S. S. and
S. C. revised the manuscript; All authors read and approved the
ﬁnal manuscript.
There are no conﬂicts of interest to declare.
References
1. Kryukov GV, Castellano S, Novoselov SV, et al. (2003)
Characterization of mammalian selenoproteomes. Science
300, 1439–1443.
2. Rayman MP (2012) Selenium and human health. Lancet 379,
1256–1268.
3. Salonen JT, Alfthan G, Huttunen JK, et al. (1982) Association
between cardiovascular death and myocardial infarction and
serum selenium in a matched-pair longitudinal study. Lancet
2, 175–179.
4. Anonymous (1979) Observations on effect of sodium
selenite in prevention of Keshan disease. Chin Med J (Engl)
92, 471–476.
5. Salonen JT, Salonen R, Seppänen K, et al. (1988) Relationship
of serum selenium and antioxidants to plasma lipoproteins,
platelet aggregability and prevalent ischaemic heart disease in
Eastern Finnish men. Atherosclerosis 70, 155–160.
1816 F. Cold et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114515003499
Downloaded from https://www.cambridge.org/core. Syddansk Universitesbibliotek, on 06 Nov 2017 at 07:47:44, subject to the Cambridge Core terms of use, available at
6. Sattler W, Maiorino M & Stocker R (1994) Reduction of
HDL- and LDL-associated cholesterylester and phospholipid
hydroperoxides by phospholipid hydroperoxide glutathione
peroxidase and Ebselen (PZ 51). Arch Biochem Biophys 309,
214–221.
7. Blankenberg S, Rupprecht HJ, Bickel C, et al. (2003)
Glutathione peroxidase 1 activity and cardiovascular events in
patients with coronary artery disease. N Engl J Med 349,
1605–1613.
8. Brigelius-Flohe R, Banning A & Schnurr K (2003) Selenium-
dependent enzymes in endothelial cell function. Antioxid
Redox Signal 5, 205–215.
9. Curran JE, Jowett JB, Elliott KS, et al. (2005) Genetic variation
in selenoprotein S inﬂuences inﬂammatory response. Nat
Genet 37, 1234–1241.
10. Gao Y, Hannan NR, Wanyonyi S, et al. (2006) Activation of the
selenoprotein SEPS1 gene expression by pro-inﬂammatory
cytokines in HepG2 cells. Cytokine 33, 246–251.
11. Vunta H, Davis F, Palempalli UD, et al. (2007) The anti-
inﬂammatory effects of selenium are mediated through
15-deoxy- Delta12,14-prostaglandin J2 in macrophages. J Biol
Chem 282, 17964–17973.
12. Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, et al.
(2006) Selenium and coronary heart disease: a meta-analysis.
Am J Clin Nutr 84, 762–773.
13. Stranges S, Marshall JR, Trevisan M, et al. (2006) Effects
of selenium supplementation on cardiovascular disease inci-
dence and mortality: secondary analyses in a randomized
clinical trial. Am J Epidemiol 163, 694–699.
14. Stranges S, Navas-Acien A, Rayman MP, et al. (2010) Selenium
status and cardiometabolic health: state of the evidence. Nutr
Metab Cardiovasc Dis 20, 754–760.
15. Bjelakovic G, Nikolova D, Gluud LL, et al. (2012) Antioxidant
supplements for prevention of mortality in healthy partici-
pants and patients with various diseases. Cochrane Database
Syst Rev 3, CD007176.
16. Rees K, Hartley L, Day C, et al. (2013) Selenium supple-
mentation for the primary prevention of cardiovascular dis-
ease. Cochrane Database Syst Rev 1, CD009671.
17. Stamler J, Wentworth D & Neaton JD (1986) Is relationship
between serum cholesterol and risk of premature death from
coronary heart disease continuous and graded? Findings in
356 222 primary screenees of the Multiple Risk Factor Inter-
vention Trial (MRFIT). JAMA 256, 2823–2828.
18. Prospective Studies Collaboration, Lewington S, Whitlock G,
et al. (2007) Blood cholesterol and vascular mortality by age,
sex and blood pressure: a meta-analysis of individual data
from 61 prospective studies with 55 000 vascular deaths.
Lancet 370, 1829–1839.
19. Jossa F, Trevisan M, Krogh V, et al. (1991) Serum selenium
and coronary heart disease risk factors in southern
Italian men. Atherosclerosis 87, 129–134.
20. Suadicani P, Hein HO & Gyntelberg F (1992) Serum selenium
concentration and risk of ischaemic heart disease in a prospective
cohort study of 3000 males. Atherosclerosis 96, 33–42.
21. Gámez C, Ruiz-López D, Artacho R, et al. (1997) Serum
selenium in institutionalized elderly subjects and relation to
other nutritional markers Letter). Clin Chem 43, 693–694.
22. Coudray C, Roussel AM, Mainard F, et al. (1997) Lipid
peroxidation level and antioxidant micronutrient status in a
pre-aging population; correlation with chronic disease pre-
valence in a French epidemiological study (Nantes, France).
J Am Coll Nutr 16, 584–591.
23. Bates CJ, Thane CW, Prentice A, et al. (2002) Selenium status
and its correlates in a British national diet and nutrition survey:
people aged 65 years and over. J Trace Elem Med Biol 16, 1–8.
24. Bleys J, Navas-Acien A, Stranges S, et al. (2008) Serum selenium
and serum lipids in US adults. Am J Clin Nutr 88, 416–423.
25. Laclaustra M, Stranges S, Navas-Acien A, et al. (2010) Serum
selenium and serum lipids in US adults: National Health and
Nutrition Examination Survey (NHANES) 2003–2004. Athero-
sclerosis 210, 643–648.
26. Stranges S, Laclaustra M, Ji C, et al. (2010) Higher selenium
status is associated with adverse blood lipid proﬁle in
British adults. J Nutr 140, 81–87.
27. Yang KC, Lee LT, Lee YS, et al. (2010) Serum selenium
concentration is associated with metabolic factors in the
elderly: a cross-sectional study. Nutr Metab (Lond) 7, 38.
28. Stranges S, Tabak AG, Guallar E, et al. (2011) Selenium status
and blood lipids: the cardiovascular risk in Young Finns study.
J Intern Med 270, 469–477.
29. Stranges S, Galletti F, Farinaro E, et al. (2011) Associations of
selenium status with cardiometabolic risk factors: an 8-year
follow-up analysis of the Olivetti Heart study. Atherosclerosis
217, 274–278.
30. Clark LC, Combs GF Jr, Turnbull BW, et al. (1996) Effects of
selenium supplementation for cancer prevention in patients with
carcinoma of the skin. A randomized controlled trial. Nutritional
Prevention of Cancer Study Group. JAMA 276, 1957–1963.
31. Levander OA, Alfthan G, Arvilommi H, et al. (1983)
Bioavailability of selenium to Finnish men as assessed by
platelet glutathione peroxidase activity and other blood
parameters. Am J Clin Nutr 37, 887–897.
32. Rayman MP, Stranges S, Grifﬁn BA, et al. (2011) Effect of
supplementation with high-selenium yeast on plasma lipids.
A randomized trial. Ann Intern Med 154, 656–665.
33. Luoma PV, Korpela H, Sotaniem EA, et al. (1985) Serum
selenium, glutathione peroxidase, lipids, and human liver
microsomal enzyme activity. A double-blind controlled trial of
selenium supplementation. Biol Trace Elem Res 8, 113–121.
34. Yu SY, Mao BL, Xiao P, et al. (1990) Intervention trial with
selenium for the prevention of lung cancer among tin miners in
Yunnan, China. A pilot study. Biol Trace Elem Res 24, 105–108.
35. Meltzer HM, Mundal HH, Alexander J, et al. (1994) Does
dietary arsenic and mercury affect cutaneous bleeding time
and blood lipids in humans? Biol Trace Elem Res 46,
135–153.
36. Meltzer HM, Folmer M, Wang S, et al. (1997) Supplementary
selenium inﬂuences the response to fatty acid-induced
oxidative stress in humans. Biol Trace Elem Res 60, 51–68.
37. Ravn-Haren G, Bugel S, Krath BN, et al. (2008) A short-term
intervention trial with selenate, selenium-enriched yeast and
selenium-enriched milk: effects on oxidative defence regulation.
Br J Nutr 99, 883–892.
38. Hawkes WC & Laslett LJ. (2009) Selenium supplementation
does not improve vascular responsiveness in healthy
North American men. Am J Physiol Heart Circ Physiol 296,
H256–H262.
39. Wu J, Salisbury C, Graham R, et al. (2009) Increased con-
sumption of wheat biofortiﬁed with selenium does not modify
biomarkers of cancer risk, oxidative stress, or immune function
in healthy Australian males. Environ Mol Mutagen 50, 489–501.
40. Larsen EH, Hansen M, Paulin H, et al. (2004) Speciation
and bioavailability of selenium in yeast-based intervention
agents used in cancer chemoprevention studies. J AOAC Int
87, 225–232.
41. Albert PS (1999) Longitudinal data analysis (repeated
measures) in clinical trials. Stat Med 18, 1707–1732.
42. Diggle PJ, Heagerty P, Liang KY, et al. (2002) Analysis of
Longitudinal Data, 2nd ed. Oxford: Oxford University Press.
43. Stender S, Dyerberg J, Bysted A, et al. (2006) A trans world
journey. Atheroscler Suppl 7, 47–52.
Selenium supplementation and lipids 1817
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114515003499
Downloaded from https://www.cambridge.org/core. Syddansk Universitesbibliotek, on 06 Nov 2017 at 07:47:44, subject to the Cambridge Core terms of use, available at
44. Van Poppel G (1998) Intake of trans fatty acids in western
Europe: the TRANSFAIR study. Lancet 351, 1099.
45. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, et al. (2011)
Nonfasting cholesterol and triglycerides and association
with risk of myocardial infarction and total mortality: the
Copenhagen City Heart Study with 31 years of follow-up.
J Intern Med 270, 65–75.
46. Unal B, Critchley JA & Capewell S. (2005) Modelling the
decline in coronary heart disease deaths in England and
Wales, 1981–2000: comparing contributions from primary
prevention and secondary prevention. BMJ 331, 614.
47. Rasmussen LB, Carlé A, Jørgensen T, et al. (2008) Iodine
intake before and after mandatory iodization in Denmark:
results from the Danish Investigation of Iodine Intake and
Thyroid Diseases (DanThyr) study. Br J Nutr 100, 166–173.
48. Haas V, Marley M, Green A, et al. (1988) Urinary iodine
excretion in a geographically stratiﬁed Danish population
sample not affected by iodination programmes. A change
towards higher values. Acta Endocrinol (Copenh) 119, 125–131.
49. Zhao SJ, Ye Y, Sun FJ, et al. (2011) The impact of dietary
iodine intake on lipid metabolism in mice. Biol Trace Elem Res
142, 581–588.
50. Jung CH, Sung KC, Shin HS, et al. (2003) Thyroid dysfunction
and their relation to cardiovascular risk factors such as lipid
proﬁle, hsCRP, and waist hip ratio in Korea. Korean J Intern
Med 18, 146–153.
51. Zimmermann MB, Aeberli I, Melse-Boonstra A, et al. (2009)
Iodine treatment in children with subclinical hypothyroidism
due to chronic iodine deﬁciency decreases thyrotropin and
C-peptide concentrations and improves the lipid proﬁle.
Thyroid 19, 1099–1104.
52. Winther KH, Bonnema SJ, Cold F, et al. (2015) Does selenium
supplementation affect thyroid function? Results from a
randomized, controlled, double-blinded trial in a Danish
population. Eur J Endocrinol 172, 657–667.
53. Duntas LH & Brenta G. (2012) The effect of thyroid disorders
on lipid levels and metabolism. Med Clin North Am 96,
269–281.
54. Sundvall J, Laatikainen T, Hakala S, et al. (2008) Systematic
error of serum triglyceride measurements during three decades
and the effect of fasting on serum triglycerides in population
studies. Clin Chim Acta 397, 55–59.
55. Hata Y & Nakajima K (2000) Life-style and serum lipids and
lipoproteins. J Atheroscler Thromb 7, 177–197.
56. Wang Z, Yao T & Song Z (2010) Chronic alcohol consumption
disrupted cholesterol homeostasis in rats: down-regulation of
low-density lipoprotein receptor and enhancement of cho-
lesterol biosynthesis pathway in the liver. Alcohol Clin Exp Res
34, 471–478.
57. Röhrig B, du Prel JB, Wachtlin D, et al. (2010) Sample
size calculation in clinical trials: part 13 of a series on
evaluation of scientiﬁc publications. Dtsch Ärztebl Int 107,
552–556.
58. Marcocci C, Kahaly GJ, Krassas GE, et al. (2011) Selenium and
the course of mild Graves’ orbitopathy. N Engl J Med 364,
1920–1931.
1818 F. Cold et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114515003499
Downloaded from https://www.cambridge.org/core. Syddansk Universitesbibliotek, on 06 Nov 2017 at 07:47:44, subject to the Cambridge Core terms of use, available at
